Last reviewed · How we verify
Prophylaxis of repetitive paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Verapamil Hydrochloride | Verapamil Hydrochloride | Pfizer Inc. | Calcium channel blocker | L-type calcium channels (slow channels) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Prophylaxis of repetitive paroxysmal supraventricular tachycardia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prophylaxis of repetitive paroxysmal supraventricular tachycardia:
- Prophylaxis of repetitive paroxysmal supraventricular tachycardia treatment updates — RSS
- Prophylaxis of repetitive paroxysmal supraventricular tachycardia treatment updates — Atom
- Prophylaxis of repetitive paroxysmal supraventricular tachycardia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prophylaxis of repetitive paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prophylaxis-of-repetitive-paroxysmal-supraventricular-tachycardia. Accessed 2026-06-10.
Related
- Prophylaxis of repetitive paroxysmal supraventricular tachycardia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing